Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Recommendation of "Buy" from Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has been given a consensus recommendation of "Buy" by the seventeen analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $33.71.

A number of research analysts have commented on DNLI shares. Deutsche Bank Aktiengesellschaft started coverage on Denali Therapeutics in a research report on Tuesday, February 11th. They issued a "buy" rating and a $31.00 price objective on the stock. Wedbush decreased their price objective on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Oppenheimer decreased their price objective on Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating on the stock in a research report on Monday, March 3rd. Robert W. Baird cut their price target on Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a research note on Thursday, May 8th. Finally, B. Riley reissued a "buy" rating and issued a $35.00 price target (down previously from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th.

Denali Therapeutics Stock Performance

DNLI traded down $0.07 during mid-day trading on Monday, reaching $15.19. The stock had a trading volume of 1,180,641 shares, compared to its average volume of 1,133,112. The stock has a market capitalization of $2.21 billion, a P/E ratio of -5.50 and a beta of 1.32. The firm's fifty day simple moving average is $14.03 and its two-hundred day simple moving average is $17.99. Denali Therapeutics has a 52 week low of $10.57 and a 52 week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same quarter in the previous year, the company posted ($0.68) earnings per share. As a group, analysts expect that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Institutional Trading of Denali Therapeutics

Several hedge funds have recently added to or reduced their stakes in DNLI. abrdn plc raised its stake in Denali Therapeutics by 10.6% during the 4th quarter. abrdn plc now owns 402,282 shares of the company's stock worth $8,199,000 after buying an additional 38,603 shares during the period. Empowered Funds LLC acquired a new position in shares of Denali Therapeutics in the fourth quarter valued at approximately $379,000. Rhumbline Advisers boosted its holdings in shares of Denali Therapeutics by 0.3% in the fourth quarter. Rhumbline Advisers now owns 190,390 shares of the company's stock valued at $3,880,000 after buying an additional 497 shares during the period. State of New Jersey Common Pension Fund D boosted its holdings in shares of Denali Therapeutics by 11.3% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 86,243 shares of the company's stock valued at $1,758,000 after buying an additional 8,760 shares during the period. Finally, Y Intercept Hong Kong Ltd boosted its holdings in shares of Denali Therapeutics by 160.5% in the fourth quarter. Y Intercept Hong Kong Ltd now owns 36,006 shares of the company's stock valued at $734,000 after buying an additional 22,183 shares during the period. Institutional investors and hedge funds own 92.92% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.